Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Malaria Diagnosed from Drop of Blood or Saliva

By LabMedica International staff writers
Posted on 13 Dec 2012
Scientists have developed a new method for diagnosing malaria based on measuring the activity of an enzyme called topoisomerase I from the Plasmodium parasite.

The technology on which the method is based is called Rolling Circle-Enhanced Enzyme Activity Detection (REEAD), which makes it possible to diagnose malaria from a single drop of blood or saliva. More...
This method is more time-effective and cost-effective than current diagnostic methods, and can be performed by personnel who have no specialized training. It can therefore be used in low-resource areas without the use of expensive equipment, clean water, or electricity.

The REEAD-based method distinguishes itself from other quick-test methods because it can measure whether a given Plasmodium infection is resistant to drugs. The newly developed technology is also the only quick-test method that makes it possible to diagnose the less common malaria parasites (P. ovale, P. knowlesi and P. malariae) in addition to the most common Plasmodium parasites (P. falciparum and P. vivax).

The high sensitivity is achieved by performing the REEAD technology within droplets surrounded by oil. The malaria parasites are distributed in the picoliter droplet, where they react effectively with the other components of the REEAD technology. The new method amplifies the signal from the malaria parasites since each parasite can give rise to more DNA molecules using the REEAD technology. Under the microscope, each DNA product is seen as a red dot.

The sensitivity, combined with its ability to detect infection in very small samples of blood or saliva, makes the method suitable for large-scale screening projects. This is of great importance in areas where the disease is close to being eradicated, and where it is therefore essential to identify and treat all patients infected with one of the above-mentioned parasites–even those who do not show symptoms of the disease.

Scientists who developed this method were led by Associate Professor Birgitta Knudsen, who is affiliated with the Interdisciplinary Nanoscience Centre (iNANO) and the Department of Molecular Biology and Genetics, Aarhus University (Denmark). Colleagues from Denmark (Department of Pathology and Department of Clinical Medicine, Aarhus University Hospital) and abroad (Duke University, University of Rome, University of St Andrews and University of Lyon) contributed to this project.

“This combination of molecular biologists, doctors, engineers, and statisticians has been important for our success in developing the new method,” said Prof. Knudsen.

The study was published in the November 2, 2012, edition of ACS Nano.

Related Links:
Aarhus University


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
Urine Analyzer
respons® UDS100
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.